The REDUCE-IT trial demonstrated that icosapent ethyl, an ethyl ester of eicosapentaenoic acid (EPA), reduced cardiovascular events in an at-risk population by a substantial degree. While the cardiovascular protective properties of this compound are now proven, several other potential uses are being actively explored in clinical studies. These areas of investigation include cancer, inflammatory bowel disease, infections, Alzheimer's disease, dementia, and depression. The next decade promises to deepen our understanding of the beneficial effects that EPA may offer beyond cardiovascular risk reduction.
CITATION STYLE
Bhatt, D. L., Hull, M. A., Song, M., van Hulle, C., Carlsson, C., Chapman, M. J., & Toth, P. P. (2020). Beyond cardiovascular medicine: Potential future uses of icosapent ethyl. European Heart Journal, Supplement, 22, J54–J64. https://doi.org/10.1093/EURHEARTJ/SUAA119
Mendeley helps you to discover research relevant for your work.